Chromosomal aberrations play a role in the leukemogenesis of acute myeloid leukemia. Some chromosomal abnormalities such as t(8;21), t(15;17), and inv(16) are frequently observed, but hundreds of uncommon chromosomal translocations also exist and their significance remains to be clarified [1] . Here we introduce a case of acute myeloid leukemia with a very rare translocation and explain its morphologic and immunophenotyping findings.
t(9;19)(q22;p13) in Acute Myelomonocytic Leukemia
To the Editor, Chromosomal aberrations play a role in the leukemogenesis of acute myeloid leukemia. Some chromosomal abnormalities such as t(8;21), t(15;17), and inv(16) are frequently observed, but hundreds of uncommon chromosomal translocations also exist and their significance remains to be clarified [1] . Here we introduce a case of acute myeloid leukemia with a very rare translocation and explain its morphologic and immunophenotyping findings.
The patient was a 50-year-old man with malaise and weakness. Paraclinical evaluation revealed leukocytosis along with anemia and thrombocytopenia (white blood cells: 24,000/µL, hemoglobin: 7.4 g/dL, platelets: 30,000/µL). Peripheral blood smear exhibited atypical blastoid cells. Subsequently the patient underwent bone marrow aspiration, which showed 80% blasts of myeloid and monocytic type with prominent cytoplasmic vacuolization. Immunophenotyping by flow cytometry revealed positive reactions for CD117, HLA-DR, MPO, and CD64. Morphologic findings and immunophenotyping were compatible with acute myelomonocytic leukemia. Bone marrow cytogenetic study showed t(9;19)(q22;p13) ( Figure 1 ). Reverse transcriptase PCR was performed for t(8;21) (AML1-ETO fusion gene) and inv(16) (CBFB-MYH11 fusion gene), which was negative for both of them. FLT3 duplication and D835 mutation were also negative. Subsequently, the patient underwent a 7+3 chemotherapy regimen with cytarabine continuous infusion (300 mg, IV) over 24 h on days 1 to 7 and daunorubicin (115 mg, IV bolus) on days 1 to 3. Although remission was achieved after induction therapy (3% blasts in bone marrow 4 weeks after chemotherapy), unfortunately the patient contracted sepsis due to neutropenia and died 1.5 months after treatment initiation.
Acute myeloid leukemia with prominent monocytic lineage involvement (M4-M5) is usually associated with determined recurrent cytogenetic aberrations like inv(16), t(v;11) (MLL gene rearrangement), and t(8;16). According to a literature review, t(9;19)(q22;p13) has been reported previously only twice. The Figure 1 . Bone marrow karyotype study revealed t(9;19)(q22;p13). first case was a 57-year-old man with acute myelomonocytic leukemia and concomitant inv(16). Exact morphologic and immunophenotyping characteristics of this case were not determined [2] . The second case was a 13-year-old boy with acute myeloid leukemia (M0) who developed multiple clonal abnormalities during his treatment course [3] . The present case is the first patient with acute myelomonocytic leukemia with t(9;19) (q22;p13) as the sole chromosomal abnormality. This cytogenetic finding and its associated morphologic and immunophenotyping characteristics are noteworthy and merit attention.
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